GleamWall
中文EN

RIGL RIGEL PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1034842 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.2%
TTM net income YoY171.1%
TTM EPS YoY159.6%
Revenue 3-yr CAGR29.6%
Net income 3-yr CAGR—

Margins

Gross margin89.6%
Operating margin26.3%
Net margin106.6%
FCF margin—
EBITDA margin27.6%

Returns

ROE109.2%
ROA80.2%
ROIC (approx.)28.7%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets15.0%
Debt / equity0.00x
Current ratio2.39x
Interest coverage18.17x

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio56.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$80.89M$78.70M$58.82M$69.80M$69.46M$101.69M$53.33M$57.60M
Cost of revenue$10.78M$8.53M$4.61M$5.96M$4.75M$4.50M$4.41M$5.79M
Gross profit$70.11M$70.18M$54.21M$63.85M$64.71M$97.18M$48.92M$51.81M
R&D expense$18.27M$13.96M$11.68M$10.69M$7.35M$6.82M$8.44M$5.63M
SG&A expense$34.73M$32.64M$30.65M$29.99M$28.94M$29.26M$27.71M$29.52M
Operating income$17.11M$23.57M$11.88M$23.17M$28.42M$61.10M$12.77M$16.66M
Interest expense$257,000$779,000$1.43M$1.70M$1.89M$1.87M$1.85M$1.96M
Pretax income$17.41M$23.59M$11.66M$22.71M$27.62M$59.98M$11.51M$15.22M
Income tax$4.22M$6.29M$3.00M-$245.35M-$280,000$369,000$65,000$881,000
Net income$13.19M$17.29M$8.65M$268.06M$27.90M$59.61M$11.45M$14.34M
EBITDA$18.90M$24.42M$12.48M$23.77M$29.02M$61.71M$13.38M$17.26M
EPS (basic)0.700.930.47—1.553.330.64—
EPS (diluted)0.650.880.44—1.463.280.63—
Weighted avg. shares (diluted)20.44M19.57M19.69M—19.16M18.16M18.17M—
Balance sheet
Cash & equivalents$46.65M$60.82M$24.41M$40.58M$48.59M$53.46M$45.78M$56.75M
Short-term investments$52.66M$34.51M$122.27M$114.38M$88.61M$54.97M$31.37M$20.57M
Receivables$56.46M$56.04M$49.95M$51.76M$45.92M$39.91M$41.55M$41.62M
Inventory$15.80M$14.37M$11.65M$11.51M$13.30M$10.42M$4.66M$6.00M
Current assets$188.52M$185.53M$234.03M$240.17M$214.93M$175.39M$146.56M$135.10M
PP&E, net———$30,000$54,000$57,000$76,000$92,000
Intangibles$94.59M$93.88M$24.16M$24.75M$25.34M$25.92M$26.51M$27.10M
Total assets$523.88M$521.07M$504.61M$513.59M$242.53M$206.74M$175.97M$163.98M
Current liabilities$78.77M$95.59M$89.49M$99.24M$94.40M$86.64M$66.63M$63.30M
Long-term debt——$45.00M$52.50M$60.00M$60.00M$60.00M$60.00M
Total debt——$45.00M$52.50M$60.00M$60.00M$60.00M$60.00M
Total liabilities$78.77M$95.64M$104.71M$122.11M$124.92M$124.80M$157.41M$160.69M
Shareholders' equity$445.11M$425.42M$399.90M$391.48M$117.61M$81.93M$18.57M$3.29M
Net debt——$20.59M$11.92M$11.41M$6.54M$14.21M$3.25M
Shares outstanding———18.31M———17.71M
Cash flow statement
Operating cash flow$34.56M$30.65M$2.73M$21.98M$24.03M$30.54M-$893,000$14.50M
Investing cash flow-$18.45M$17.45M-$7.97M-$25.36M-$33.17M-$23.28M-$10.55M-$10.91M
Financing cash flow-$30.29M-$11.70M-$10.92M-$4.57M$4.27M$418,000$484,000$1.47M
Depreciation & amortization$1.79M$848,000$597,000$601,000$603,000$607,000$604,000$604,000
Stock-based compensation$4.85M$6.84M$3.46M$2.75M$3.36M$3.28M$3.32M$2.09M
Share buybacks$1.02M$511,000$3.74M—$0$0$0—

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.